香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年年度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年3 月2 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅供識別 上海复星 ...

Core Viewpoint - The company has entered into a licensing agreement with Eisai Co., Ltd. for the development, production, and commercialization of Hanshu (sulunat) injection in Japan, which is aimed at treating tumor indications [1][2]. Group 1: Licensing Agreement Details - The company will receive an upfront payment of $75 million upon signing the licensing agreement [1]. - Regulatory milestone payments could total up to $80.1 million based on the achievement of various regulatory milestones for the licensed product in the region [1]. - Commercial sales milestone payments could reach approximately $233 million, contingent on the annual net sales levels of the licensed product in the region [1]. - The company will also receive royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region [1]. Group 2: Product Information and Market Expansion - Hanshu (sulunat) is an innovative anti-PD-1 monoclonal antibody developed by the company, already approved for multiple indications in mainland China, including sq-NSCLC, ES-SCLC, ESCC, and nsq-NSCLC [2]. - The product has also received approvals in several countries/regions, including the EU, UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India, and has been granted orphan drug status by regulatory authorities in the US, EU, Switzerland, and South Korea [2]. - The company is advancing multiple clinical trials globally for Hanshu and related combination therapies, covering indications such as lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastric cancer [2]. - The collaboration with Eisai is expected to enhance the company's overseas market presence and improve the accessibility and recognition of its products in international markets, thereby creating conditions for sustained revenue growth [2].

Core Viewpoint - The company Fuhong Hanlin (02696) has received acceptance for its New Drug Application (NDA) for Hansuzhuang (sulizumab injection) in combination with platinum-based chemotherapy for the treatment of PD-L1 positive, resectable gastric cancer patients, which has been prioritized for review by the National Medical Products Administration (NMPA) [1] Group 1 - The NDA acceptance is aimed at expediting the review process for the new indication of Hansuzhuang [1] - The application is based on a Phase 3 clinical study that compared Hansuzhuang combined with chemotherapy against placebo combined with chemotherapy for the neoadjuvant/adjuvant treatment of gastric cancer patients [1] - The study results demonstrated that Hansuzhuang combined with chemotherapy significantly extended the event-free survival (EFS) of patients, meeting the predefined superiority criteria, and showed better safety and tolerability compared to standard chemotherapy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 漢斯狀® （斯魯利單抗注射液）聯合化療用 於胃癌新輔助/輔助治療的上市註冊申請(NDA) 獲國家藥品監督管理局(NMPA)受理，並已納入優先審評 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，本公司自主開發的漢斯狀® （斯魯 利單抗注射液）（「漢斯狀®」）聯合含鉑化療新輔助，在手術後輔助治療，用於 PD-L1陽性的、可手術切除的胃癌患者的上市註冊申請(NDA)獲國家藥品監 督管理局(NMPA)藥品審評中心受理，並已納入優先審評審批程序，將加速 其上市審評進程。 B. 申報背景及依據 本次漢斯狀®新適應症的上市註冊 ...

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Pfizer for the exclusive global development, production, and commercialization rights of a small molecule GLP-1 receptor agonist (including YP05002) developed by its subsidiary, Yaoyou Pharmaceutical [1][5]. Group 1: Licensing Agreement Details - Yaoyou Pharmaceutical will conduct Phase I clinical trials of YP05002 in Australia and grant Pfizer exclusive rights for further global development and commercialization [1]. - Fosun Pharma will receive an upfront payment of $150 million and may earn up to $1.935 billion in milestone payments related to specific development, registration, and commercialization achievements, along with tiered royalties after product approval [1][2]. Group 2: Strategic Importance - This collaboration with Pfizer marks a significant milestone in Fosun Pharma's strategy for innovation and internationalization, aiming to address unmet clinical needs in metabolic diseases [5]. - The company has strengthened its global operational capabilities, focusing on innovation, licensing, production, and commercialization [5]. Group 3: Broader Industry Context - The licensing agreement is part of a larger trend where Chinese innovative pharmaceutical companies are increasingly engaging in international collaborations, with total licensing-out amounts exceeding $100 billion in 2025 [9]. - Other companies, such as Innovent Biologics and Hengrui Medicine, have also secured significant licensing agreements, indicating a robust growth trajectory for the Chinese pharmaceutical industry in global markets [9][11].

Core Insights - China National Pharmaceutical Group (Sinopharm) has renewed its distribution partnership with Fuhong Hanlin, which will last from January 1, 2026, to December 31, 2028, focusing on the commercialization of innovative biopharmaceutical products [1][10]. Group 1: Partnership with Fuhong Hanlin - Fuhong Hanlin, a biopharmaceutical company, has a strong product matrix and approximately 50 molecules in development, ensuring a stable supply of new products for Sinopharm [3][5]. - The sales cap for the renewed partnership is set at 12.224 billion RMB over three years, with expected sales growth driven by new product launches and existing product demand [5][17]. - Specific sales growth expectations include a 0.8% increase in 2027 and a 14.2% increase in 2028, attributed to new indications and innovative products [5][17]. Group 2: Strategic Collaborations - Sinopharm is accelerating collaborations with upstream industrial partners, including a recent strategic partnership with Pierre Fabre, a French pharmaceutical company [5][19]. - The company is also engaging with other multinational pharmaceutical giants like AstraZeneca and Bristol-Myers Squibb to explore strategic synergies and innovative business models [19][20]. - Domestic collaborations are also progressing, with Sinopharm partnering with Tianjin Pharmaceutical Group to enhance channel integration and product offerings [21][22]. Group 3: Retail and Operational Performance - Sinopharm's retail arm, Guoda Pharmacy, is transforming its procurement system and has seen a 11.3% year-on-year sales growth in core products from industrial partners in the first half of 2025 [23]. - The company reported a revenue of 431.5 billion RMB in the first three quarters of 2025, with a reduced year-on-year decline of 2.47% [23]. - Recent leadership changes, including the resignation of Chairman Zhao Bingxiang, signal a potential shift in strategic direction for Sinopharm [24].

Core Insights - Fosun Pharma has successfully treated over 84 million severe malaria patients in Africa with its artemisinin-based products, showcasing its commitment to addressing unmet clinical needs [1] - The company has established a clear strategic focus for the 14th Five-Year Plan, emphasizing innovation, deep internationalization, and embracing AI as key pillars for high-quality development [1][7] - Fosun Pharma has achieved significant milestones in innovation, including the launch of 12 self-developed and licensed innovative drugs during the 14th Five-Year Plan [1][4] Innovation and Product Development - Fosun Pharma has developed several firsts in the industry, including China's first self-developed biosimilar drug Hanlikang and the first CAR-T cell therapy product Yikaida [2][3] - The company has built a comprehensive innovation system with four core technology platforms: small molecules, antibodies, ADCs, and cell therapy, enabling full-cycle innovation from R&D to commercialization [3] Financial Performance - In the first three quarters of 2025, Fosun Pharma's innovative drug revenue exceeded 6.7 billion yuan, reflecting an 18.09% year-on-year growth [4] - The company aims to continue optimizing its innovation pipeline value over the next five years, focusing on unmet clinical needs [4] Global Expansion Strategy - Fosun Pharma has actively expanded its global market presence, with its anti-tumor innovative drug approved in approximately 40 countries and regions during the 14th Five-Year Plan [5][6] - The company has established a marketing team of over 1,000 people and a network covering more than 110 countries, emphasizing localized strategies for different markets [6] Embracing AI in Development - Fosun Pharma is committed to integrating AI into its operations, viewing it as a tool for enhancing R&D efficiency and organizational evolution [7][8] - The company has launched its internally developed PharmAID decision-making platform, which is already being utilized in various stages of drug development [7][8]

Core Viewpoint - The company has received official inclusion of its innovative anti-PD-1 monoclonal antibody, Hanshuo (Sru Li Single Antibody Injection), in the breakthrough therapy drug program by the National Medical Products Administration (NMPA) for the neoadjuvant/adjuvant treatment of gastric cancer [1] Group 1 - Hanshuo has been approved for multiple indications in mainland China, including first-line treatment for squamous non-small cell lung cancer (sq-NSCLC), extensive small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsq-NSCLC) [1] - The drug has also received approvals in various countries/regions including the EU, UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India, and has been granted orphan drug designation by regulatory authorities in the US, EU, Switzerland, and South Korea [1] - The company is actively advancing multiple clinical trials for Hanshuo and related combination therapies globally, covering a wide range of indications including lung cancer, esophageal cancer, head and neck squamous cancer, colorectal cancer, and gastric cancer [1]

Core Viewpoint - The announcement highlights the inclusion of Hanshuo (Sruilumab injection) in the National Medical Products Administration (NMPA) breakthrough therapy program for the neoadjuvant/adjuvant treatment of gastric cancer, indicating a significant advancement for the company in the oncology sector [1] Group 1: Product Development - Hanshuo is an innovative anti-PD-1 monoclonal antibody developed by the company, which has already been approved for various indications in mainland China, including first-line treatment for squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsq-NSCLC) [1] - The product has also received approvals in multiple countries/regions, including the EU, UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India, and has been granted orphan drug designation by regulatory authorities in the US, EU, Switzerland, and South Korea [1] Group 2: Clinical Trials - The company is actively advancing multiple clinical trials for Hanshuo and related combination therapies globally, covering a wide range of indications such as lung cancer, esophageal cancer, head and neck squamous cancer, colorectal cancer, and gastric cancer [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 | 產品/聯合療法 | 適應症 | 最新進展 | | --- | --- | --- | | 漢斯狀®+化療 | 廣泛期小細胞肺癌 | 於美國處於橋接試驗中 | | | | 於日本處於橋接試驗中 | | | 胃癌新輔助/輔助 | 於中國境內處於3期臨 | | | | 床試驗中，已達到主要 | | | | 研究終點 | | | 局限期小細胞肺癌（漢 | 於中國境內、美國、澳 | | | 斯狀®聯合化療同步放 | 大利亞及歐盟國家處於 | | | 療） | 3期臨床試驗中（國際 | | | | 多中心試驗） | | 漢斯狀®+貝伐珠單抗+化 | 轉移性結直腸癌 | 於中國境內、日本、印 | | 療 | | 度尼西亞處於2/3期臨 | | ...